Announcing our Investment in Biolevate: From AI Medical Writing to Accelerating Healthcare Innovation

By Julien Hobeika, Naza Metghalchi, Pierrick Cudonnec

At EQT Ventures, we have the privilege of partnering with visionary entrepreneurs who are redefining the future of healthcare through technology. Over the past two years, we’ve closely observed the challenges scientists face in bringing new medical innovations to market (see our perspectives on this here). Despite significant advancements in AI and a surge in multimodal data, the journey from research to patient care remains costly, complex, and time-consuming.

Scientists are at the heart of this journey, navigating through vast amounts of data, rigorous regulatory requirements, and the need for precise documentation. Each phase — from initial research and development to clinical trials and market access — involves intricate processes that require both accuracy and efficiency. With growing workforce shortages and an ever-increasing demand for new therapies, the need to empower scientists at every step has never been more critical.

Imagine if we could leverage AI to support scientists throughout their entire workflow — accelerating research, simplifying compliance, and bringing life-saving treatments to patients faster.

Meet Biolevate: an AI company accelerating healthcare innovation by empowering scientists in every phase of development.

Biolevate has developed ELISE, a proprietary AI platform designed to assist scientists and researchers across all stages of the medical innovation process. Leveraging the new paradigm of AI technologies, ELISE offers a unified solution that enhances data/document analysis, streamlines compliance, and optimizes the creation and management of essential documents.

We’ve been excited by:

1. The Team: Behind this approach is a team uniquely equipped to tackle the complexities of building a technically challenging product, and one that understands the needs of regulated industries. We’ve known Joel, Biolevate’s CEO, for many years. He joined Dataiku in 2015 as an early employee and was a key enabler for many of its tech developments, but also for its commercial successes. Like any great founder we work with, Joel’s ability to overcome adversity is second to none. He exudes a rare blend of technical insights and personal passion driving Biolevate’s mission to bring LLM capabilities to a group of customers that were historically left out. Equally, his co-founder Nathan, with a background from medical companies such as Coloplast, has been instrumental in shaping Biolevate’s foundations. His keen understanding of user experience, combined with his global network are vital to Biolevate’s success in creating a product solving an astute need.

2. The Timing: With the increasing complexity of medical research and the pressing need for new therapies, Biolevate’s solution arrives at a pivotal moment. Many healthcare organizations are looking to empower their in-house scientific teams with AI tools, rather than relying solely on external research organizations

3. The Unique Positioning of the Product: Biolevate’s AI-driven platform ELISE, offers a suite of features designed to support scientists and researchers throughout the medical innovation process. The product is leveraging new AI technology on every aspect of unstructured data in healthcare. It blends:

• Metadata extraction and document intelligence
• Real-time collaborative, version controlled, regulatory-compliant medical document editing and creation.
• Literature Research & Monitoring, to combine intelligence from your own internal documentations and knowledge with externally available intel.

It’s always inspiring to find a team that has built the right product at the right time. Biolevate is delivering the technological capabilities that scientists and healthcare companies are desperately looking for.

We believe that by making AI accessible and empowering scientists at every step, Biolevate is spearheading a new paradigm in the healthcare industry.

Today, we’re proud to be leading their €6 million seed funding round alongside industry leaders like Mehdi Ghissassi, head of product at Deepmind, and the co-founders of Zoi.

A warm welcome to Joel, Nathan, and the entire Biolevate team to EQT Ventures!

PS. At EQT Ventures, we believe that vertical software is having a renaissance. We are excited to see new cohorts of companies like Biolevate tackling markets that have historically been lagging in software adoption, and finally having their “why now” moment. If you are building in Vertical AI, reach out to us.

julien.hobeika@eqtventures.com